{"id":9957,"date":"2026-05-22T02:00:00","date_gmt":"2026-05-22T00:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=45cc366c96dd93b126df286f0383f58c"},"modified":"2026-05-22T02:00:00","modified_gmt":"2026-05-22T00:00:00","slug":"artera-presents-multiple-asco-2026-abstracts-on-multimodal-ai-mmai-risk-stratification-and-treatment-decisions-in-cancer","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=9957","title":{"rendered":"Artera Presents Multiple ASCO 2026 Abstracts on Multimodal AI (MMAI) Risk Stratification and Treatment Decisions in Cancer"},"content":{"rendered":"<ul class=\"bwlistdisc\">\n<li>\nValidation of MMAI in node-positive HR+ breast cancer to determine chemotherapy benefit<\/li>\n<li>\nConcordance analysis between MMAI and 21-gene Recurrence Score test in breast cancer<\/li>\n<\/ul><p>SAN FRANCISCO--(BUSINESS WIRE)--<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fartera.ai%2F&amp;esheet=54539144&amp;newsitemid=20260521757142&amp;lan=en-US&amp;anchor=Artera&amp;index=1&amp;md5=f59dc9402afc014451420fdea4abcf5a\" rel=\"nofollow\" shape=\"rect\">Artera<\/a>, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, will present multiple abstracts at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, May 29\u2013June 2, 2026, in Chicago.<\/p><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260521757142\/en\/2811183\/5\/Full_Color_Primary_Vertical_NO_Padding_LT_BG.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260521757142\/en\/2811183\/22\/Full_Color_Primary_Vertical_NO_Padding_LT_BG.jpg\" \/><\/a><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260521757142\/en\/2811183\/5\/Full_Color_Primary_Vertical_NO_Padding_LT_BG.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260521757142\/en\/2811183\/21\/Full_Color_Primary_Vertical_NO_Padding_LT_BG.jpg\" \/><\/a><p>\nTwo breast cancer abstracts demonstrate the performance of Artera\u2019s MMAI across clinically challenging settings. One study assesses prognosis and chemotherapy benefit stratification in node\u2011positive HR+ breast cancer, and a separate study evaluates the prognostic performance of MMAI against the 21\u2011gene Recurrence Score test in a retrospective node\u2011negative disease cohort.<\/p><p>\n\u201cThese studies expand our understanding of how Artera performs across increasingly complex breast cancer populations,\u201d said Calvin Chao, MD, PhD, Vice President of Medical Science at Artera. \u201cTogether, they reinforce the ability of MMAI to provide more refined risk assessment in both node-negative and node-positive disease and further support treatment decision-making for clinicians and patients.\u201d<\/p><p>\nThe breast cancer data being presented at ASCO 2026 builds on recent momentum in this disease area following the U.S. Food and Drug Administration <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.businesswire.com%2Fnews%2Fhome%2F20260506413700%2Fen%2FArtera-Receives-U.S.-FDA-Clearance-for-ArteraAI-Breast-Expanding-Its-AI-Platform-to-Breast-Cancer&amp;esheet=54539144&amp;newsitemid=20260521757142&amp;lan=en-US&amp;anchor=%28FDA%29+clearance+of+ArteraAI+Breast&amp;index=2&amp;md5=6ff8c4128eb31d973b36c2b368a7c95a\" rel=\"nofollow\" shape=\"rect\">(FDA) clearance of ArteraAI Breast<\/a>, a software\u2011as\u2011a\u2011medical\u2011device (SaMD) for risk stratification in early\u2011stage HR\u2011positive, HER2\u2011negative invasive breast cancer.<\/p><p>\nArtera will also be exhibiting at ASCO 2026 at Booth #11047, where attendees can learn more about the Artera platform.<\/p><p>\n<b>Breast Cancer Presentations at ASCO 2026<\/b><\/p><p>\n<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2F260430&amp;esheet=54539144&amp;newsitemid=20260521757142&amp;lan=en-US&amp;anchor=Oral+Presentation&amp;index=3&amp;md5=caef106076329812c5c68a277ba2f886\" rel=\"nofollow\" shape=\"rect\">Oral Presentation<\/a>: External validation of a MMAI model for prognosis and chemotherapy benefit prediction in postmenopausal, node-positive, hormone receptor\u2013positive breast cancer patients: Analysis of SWOG S8814\n<br\/><b>Abstract Number:<\/b> #107\n<br\/><b>Session Type and Title<\/b>: Oral Session \u2013 Clinical Science Symposium\n<br\/><b>Date and Time:<\/b> June 1st, Hall D1, 9:45\u201311:15 AM CT\n<br\/><b>Summary: <\/b>This study extends prior validation of MMAI in node\u2011negative disease into node\u2011positive HR+ breast cancer, addressing the clinically challenging 1\u20133 node population where uncertainty about chemotherapy benefit is common.<\/p><p>\n<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2F267881&amp;esheet=54539144&amp;newsitemid=20260521757142&amp;lan=en-US&amp;anchor=Poster+Presentation&amp;index=4&amp;md5=71c54107b6f83ebe98579baa25c07b8c\" rel=\"nofollow\" shape=\"rect\">Poster Presentation<\/a>: Prognostic Performance of a Multimodal Artificial Intelligence Histopathology-Based Tool Versus the 21-Gene Recurrence Score in Early-Stage Breast Cancer\n<br\/><b>Abstract Number:<\/b> #559\n<br\/><b>Session Type and Title<\/b>: Poster Session \u2013 Breast Cancer \u2013 Local\/Regional\/Adjuvant\n<br\/><b>Date and Time:<\/b> June 1st, Hall A, 1:30\u20134:30 PM CT\n<br\/><b>Summary: <\/b>The study demonstrated strong concordance between MMAI and the 21\u2011gene Recurrence Score test in identifying low\u2011risk patients with favorable outcomes, while providing additional prognostic clarity in low and intermediate\u2011risk disease, using digital pathology images without additional tissue consumption.<\/p><p>\n<b>Prostate Cancer Presentations at ASCO 2026<\/b><\/p><p>\nIn addition to breast cancer, Artera will also present data in localized prostate cancer, further supporting the robustness and generalizability of its platform.<\/p><p>\n<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2F260765&amp;esheet=54539144&amp;newsitemid=20260521757142&amp;lan=en-US&amp;anchor=Poster+Presentation&amp;index=5&amp;md5=0933b8f24b9132a93b5e84d743e0e4bf\" rel=\"nofollow\" shape=\"rect\">Poster Presentation<\/a>: Image-Only and Multimodal AI Digital Pathology Biomarkers Demonstrate Consistent Risk Stratification Across Standard Prostate Cancer Management Strategies\n<br\/><b>Abstract Number:<\/b> #5023\n<br\/><b>Session Type and Title<\/b>: Poster Session \u2013 Genitourinary Cancer \u2013 Prostate, Testicular, and Penile\n<br\/><b>Date and Time:<\/b> May 31st, Hall A, 9:00 AM\u201312:00 PM CT\n<br\/><b>Summary: <\/b>Building on data previously presented at the Society of Urologic Oncology Annual Meeting 2025 and published in <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Freviewsinurology.com%2Fissues%2Fvol%2F25%2Fno%2F1%2Fvalidation-of-multimodal-and-image-only-artificial-intelligence-digital-pathology-based-biomarkers-using-multi-institutional-real-world-data&amp;esheet=54539144&amp;newsitemid=20260521757142&amp;lan=en-US&amp;anchor=Reviews+in+Urology&amp;index=6&amp;md5=d4bb7a89d5e54d807ad4c86094ae36ab\" rel=\"nofollow\" shape=\"rect\">Reviews in Urology<\/a>, this study further demonstrates that image-only and multimodal AI models derived from routine pathology can consistently stratify metastatic risk in localized prostate cancer across multiple-institutional real-world cohorts, despite differences in standard management strategies.<\/p><p>\n<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2F260769&amp;esheet=54539144&amp;newsitemid=20260521757142&amp;lan=en-US&amp;anchor=Poster+Presentation&amp;index=7&amp;md5=0b4c139c0a373ae2570d6e566d8ed687\" rel=\"nofollow\" shape=\"rect\">Poster Presentation<\/a><b>:<\/b> Assessing the Clinical and Biological Associations Between Multimodal Artificial Intelligence (MMAI) and 22-Gene Genomic Classifier (GC) in Localized Prostate Cancer (PCa)\n<br\/><b>Abstract Number: <\/b>#539640\n<br\/><b>Session Type and Title<\/b>: Poster Session \u2013 Genitourinary Cancer \u2013 Prostate, Testicular, and Penile\n<br\/><b>Date and Time:<\/b> May 31st, Hall A, 9:00 AM\u201312:00 PM CT\n<br\/><b>Summary: <\/b>This exploratory study compares MMAI with a 22\u2011gene genomic classifier in localized prostate cancer, showing that both are associated with outcomes while often assigning risk differently, building on prior validation of MMAI presented by Melvin Chua, MD, PhD, at ASTRO 2025 in an Asian patient cohort, supporting its performance across diverse populations.<\/p><p>\n<b>About Artera<\/b><\/p><p>\nArtera is a global leader in precision medicine, leveraging multimodal artificial intelligence (MMAI) to personalize cancer care. Artera\u2019s MMAI platform leverages a patient\u2019s digitized histopathology images along with the patient\u2019s clinical data to determine cancer aggressiveness and predict therapy benefit. This approach has been validated in multiple Phase 3 randomized trials across different cancers and is available in multiple versions across the globe.<\/p><p>\nArtera\u2019s FDA-authorized software products include ArteraAI Prostate (de novo authorization) and ArteraAI Breast (510(k) clearance). In addition, Artera has received CE Marking for its prostate and breast cancer in vitro diagnostic tests, supporting regulated availability in international markets.<\/p><p>\nArtera\u2019s flagship product, the ArteraAI Prostate Test, is commercially available as a laboratory-developed test in the US and internationally through its distribution partners. The ArteraAI Prostate Test is the first of its kind to deliver both prognostic and predictive insights for patients with prostate cancer, empowering clinicians and patients to make more informed treatment decisions.<\/p><p>\nArtera\u2019s headquarters is based in Los Altos, California, while its CLIA-certified and clinical laboratory is located in Jacksonville, Florida. For more information about Artera, visit <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fartera.ai&amp;esheet=54539144&amp;newsitemid=20260521757142&amp;lan=en-US&amp;anchor=artera.ai&amp;index=8&amp;md5=100ffef3716d8e389fa1fccea925c33e\" rel=\"nofollow\" shape=\"rect\">artera.ai<\/a><a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fartera.ai&amp;esheet=54539144&amp;newsitemid=20260521757142&amp;lan=en-US&amp;anchor=.&amp;index=9&amp;md5=f89a35331ec47079cab2773cc7e1c4ac\" rel=\"nofollow\" shape=\"rect\">.<\/a><\/p><br\/> <b>Contacts<\/b> <br\/><p>\nMedia:\n<br\/>Vanessa Donohue\n<br\/>Antenna Group\n<br\/><a  href=\"mailto:artera@antennagroup.com\" rel=\"nofollow\" shape=\"rect\">artera@antennagroup.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Validation of MMAI in node-positive HR+ breast cancer to determine chemotherapy benefit<\/p>\n<p>Concordance analysis between MMAI and 21-gene Recurrence Score test in breast cancer<br \/>\nSAN FRANCISCO&#8211;(BUSINESS WIRE)&#8211;Artera, the developer of multimodal artifici&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-9957","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/9957","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=9957"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/9957\/revisions"}],"predecessor-version":[{"id":9958,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/9957\/revisions\/9958"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=9957"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=9957"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=9957"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}